ProciseDx Achieves CE Mark for Fecal Calprotectin Point of Care Testing News provided by Share this article Share this article SAN DIEGO, Feb. 23, 2021 /PRNewswire/ -- ProciseDx Inc. announced today that it has received CE mark for its Fecal Calprotectin (Procise FCP™) point of care tests for use on the ProciseDx™ system. Offering a point of care test for fecal calprotectin will help many physicians expedite their diagnosis of Crohn's Disease or Ulcerative Colitis, as well as other digestive conditions. The test can be completed in under 5 minutes with the ProciseDx platform. The ProciseDx instrument is about the size of a shoe box and can provide diagnostics results in as little as 2 minutes from a finger prick drop of blood. Procise FCP uses stool from our patient home use Stool Collection Device.